RUNX2 and colorectal carcinoma: MALAT1 was reported to target several CRC-related pathways such as Wnt/β-catenin, YAP, SOX9, RUNX2, Snail, EGF, PI3K/AKT/mTOR, P53, and VEGF [34, 35].